Glaxo signs deal with Chroma 'worth £1bn'
Wednesday 24 June 2009
Glaxosmithkline, Europe's biggest pharmaceutical company, continued its policy of doing small scale partnership deals and eschewing so-called mega mergers yesterday by penning an exploratory agreement with biotechnology group Chroma.
The deal, which could eventually be worth as much as $1bn, gives GSK access to a technology that Oxford-based Chroma claims helps molecules suppress identifiable cells more efficiently, and with fewer side effects. The deal is centred on compounds developed to treat inflammatory diseases, such as rheumatoid arthritis.
Ian Nicholson, the chief executive of privately-owned Chroma refused to say how much GSK had paid up-front, but the pharma giant has decided to enter the agreement even before the technology has passed "proof-of-concept" assessments, only after which can it be tested on patients. Under the deal GSK will pay Chroma so-called milestones as the technology clears certain regulatory hurdles, and will get the licence to market the drugs, paying Chroma a royalty on any sales.
"We are delighted to collaborate with GSK to advance novel targeted therapies using our technology. This collaboration provides strong validation of our technology platform and will enable Chroma to progress a broad pipeline of novel agents against a range of serious diseases," said Mr Nicholson.
GSK, which also participated in Chroma's £15m equity raising yesterday, has signed several early stage deals in recent months. "This agreement marks GSK's continued efforts to access the best science and technology platforms worldwide. We believe Chroma's platform has tremendous potential, and look forward to working with Chroma to accelerate the discovery and development of innovative new medicines for patients," said Shelagh Wilson, a vice president at the company.
Mr Nicholson also revealed that Chroma is considering a public listing.
- 1 Pope Francis issues top 10 tips for happiness
- 2 Disney heiress Abigail disowns her share of family profits in West Bank company
- 3 The secret report that helps Israel hide facts
- 4 Now diplomacy has failed, boycotting Israel might be the only way we can protect the people of Gaza
- 5 Israel's propaganda machine is finally starting to misfire
Russell Brand accuses Sean Hannity of terrorism after aggressive Israel-Gaza debate
Pope Francis issues top 10 tips for happiness
Justin Bieber posts Instagram photo of a crying Orlando Bloom after Ibiza fight 'over Miranda Kerr'
Disney heiress Abigail disowns her share of family profits in West Bank company
Air Algerie AH5017 crash: Jet fell 30,000 feet in three minutes ‘due to violent storm’
The secret report that helps Israel hide facts
Land for gas: Merkel and Putin discussed secret deal could end Ukraine crisis
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Boozy, ignorant, intolerant, but very polite – Britain as others see us
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
£28000 - £32000 per annum + benefits: Ashdown Group: Training Programme Manage...
£20000 - £24000 per annum: Harrington Starr: A leading provider of web based m...
£28000 - £32000 per annum: Ashdown Group: Secretary (Sales Team Support) - Mat...